Marie Brizard Wine & Spirits: Q4 2025 and full-year 2025 revenues Charenton-le-Pont, 19 February 2026 Q4 2025 and full-year 2025 revenues FY 2025 revenues: €172.0m (-8.6%1 vs 2024) Q4 2025 revenues: €44.6m (-6.9%1) Significant slowdown in the global spirits market;French market impacted by delistings over most of the year France: revenues fell by 12.9% to €19.2 million in Q4 2025 due to complicated annual trade negotiations with Off-Trade customers. The gradual resumption of listings for the William Peel brand at the end of the quarter failed to...
Marie Brizard Wine & Spirits: Activité du 4ème trimestre 2025 et de l’année 2025 Charenton-le-Pont, le 19 février 2026 Activité du 4ème trimestre 2025 et de l’année 2025 Chiffre d’affaires 2025 : 172,0 M€ (- 8,6 %1 vs 2024) Chiffre d’affaires du 4ème trimestre : 44,6 M€ (- 6,9 %1) Net ralentissement du marché global des spiritueux, et impact en France des déréférencements pendant la majeure partie de l’année France : recul des ventes à 19,2 M€ (-12,9 %) au 4ème trimestre 2025, du fait des négociations commerciales annuelles compliquées a...
A director at Kaufman & Broad sold 1,952 shares at 32.100EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
Fagron delivered a solid FY25 performance, with revenue coming in 1% above CSS expectations, mainly supported by betterthanexpected growth in North America. REBITDA reached €193m, coming in 1.6% above CSS expectations, as all regions reported slightly higher margins than anticipated. Regionally, EMEA posted the strongest overall growth, driven by acquisitions, while North America and LatAm delivered DD organic growth at CER. For FY26, Fagron expects M to HSD organic growth at CER and a modest im...
Flow Traders 4Q and FY 2025 Results Flow Traders 4Q and FY 2025 Results Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited 4Q and FY 2025 results. Highlights Flow Traders recorded Net Trading Income of €123.8m and Total Income of €121.0m in 4Q25, a decrease of 20% and 24% when compared to 4Q24, respectively. For full year 2025, Net Trading Income came in at €485.8m and Total Income at €480.5m, increases of 4% and 0% year-on-year, respectively.Flow Traders’ ETP Value Traded increased by 22% in 4Q25 to €516bn in 4Q24. Full year Flow Traders’ ETP Value T...
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Strong revenue growth with 9.2% reported growth (12.9% at CER1) to reach €952.2 million, ahead of guidance and supp...
Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9% Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 12 februari 2026 – 7:00 AM CET Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9% Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar jaarresultaten voor de periode eindigend op 31 december 2025. Belangrijkste hoogtepunten Sterke omzetgroei met een gerapporteerde stijging van 9,2% (12,9% tege...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.